Abstract
Infections with a range of common community viruses remain a major cause of mortality and morbidity after allogeneic hematopoietic stem cell transplantation. T cells specific for cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenoviruses can safely prevent and infections with these three most common culprits, but the manufacture of individual T cell lines for each virus would be prohibitive in terms of time and cost. We have demonstrated that T cells specific for all three viruses can be manufactured in a single culture using monocytes and EBV-transformed B lymphoblastoid cell lines (LCLs), both transduced with an adenovirus vector expressing pp65 of CMV, as antigen-presenting cells. Trivirus-specific T cell lines produced from healthy stem cell donors could prevent and treat infections with all three viruses, not only in the designated recipient, but in unrelated, partially-HLA-matched third party recipients. We now provide the details and logistics of T cell manufacture.
Acknowledgments
This work was supported by NIH grants CA-61384 (HEH and CMR) and clinical grade CTLs were produced by Production Assistance for Cellular Therapies (NHLBI-PACT) (N01-HB-37163) (CMR and APG). The pp65 vector was provided by a grant from the National Gene Vector Laboratories (NIH-NCRR U42 RR16578). The authors declare no competing financial interests.
Disclaimer: The information in this article is intended for educational purposes only and should not be considered as a standard of care or recommended treatment for any particular patient.